State Of New Jersey Common Pension Fund D Fibrogen Inc Transaction History

State Of New Jersey Common Pension Fund D

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 02, 2023	BUY	$2.49 - $20.59 $82,194 - $679,675	33,010 Added 31.18%	138,888 $374,000
Q1 2023 Apr 26, 2023	SELL	$15.95 - $25.18 $968,787 - $1.53 Million	-60,739 Reduced 36.45%	105,878 $1.98 Million
Q4 2022 Feb 01, 2023	BUY	$13.27 - $17.73 $2.21 Million - $2.95 Million	166,617 New	166,617 $2.67 Million
Q3 2021 Oct 27, 2021	SELL	$10.18 - $26.64 $1.22 Million - $3.19 Million	-119,822 Closed	0 $0
Q2 2021 Jul 23, 2021	BUY	$18.57 - $35.68 $1.19 Million - $2.29 Million	64,125 Added 115.13%	119,822 $3.19 Million
Q1 2021 Apr 27, 2021	SELL	$31.0 - $55.72 $35,929 - $64,579	-1,159 Reduced 2.04%	55,697 $1.93 Million
Q4 2020 Feb 03, 2021	SELL	$37.09 - $48.97 $182,260 - $240,638	-4,914 Reduced 7.96%	56,856 $2.11 Million
Q3 2020 Oct 27, 2020	BUY	$40.47 - $45.5 $28,450 - $31,986	703 Added 1.15%	61,770 $2.54 Million
Q2 2020 Aug 04, 2020	SELL	$32.57 - $42.83 $84,063 - $110,544	-2,581 Reduced 4.06%	61,067 $2.48 Million
Q3 2019 Oct 23, 2019	BUY	$36.98 - $48.45 $1.7 Million - $2.23 Million	46,000 Added 260.65%	63,648 $2.35 Million
Q3 2017 Oct 25, 2017	BUY	$33.4 - $53.9 $589,443 - $951,227	17,648	17,648 $949,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of State Of New Jersey Common Pension Fund D, based on Form 13F filings with the SEC.

Stay updated on State Of New Jersey Common Pension Fund D with notifications on news.